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ABSTRACT
An increasing number of potent antiplatelet and
anticoagulant medications are being used for the long-
term management of cardiac, cerebrovascular, and
peripheral vascular conditions. Management of these
medications in the perioperative and peri-injury settings
can be challenging for surgeons, mandating an
understanding of these agents and the risks and benefits
of various management strategies. In this two part
review, agents commonly encountered by surgeons in
the perioperative and peri-injury settings are discussed
and management strategies for patients on long-term
antiplatelet and anticoagulant therapy reviewed.
In part one, we review warfarin and the new direct oral
anticoagulants. In part two, we review antiplatelet
agents and assessment of platelet function and the
perioperative management of long-term anticoagulation
and antiplatelet therapy.
INTRODUCTION
For decades, aspirin and warfarin have been the
predominant antiplatelet and anticoagulant alterna-
tives. Beginning with the introduction of the anti-
platelet agent clopidogrel in 2002, several more
potent oral antiplatelet and oral anticoagulant
agents have been approved for use. The increase in
the number of therapeutic agents and the popula-
tion at risk requires that surgeons have an under-
standing of the risks and benefits of reversing these
agents in various settings and an understanding of
the most appropriate methods for doing so. In part
one of this practice management overview (in the
prior issue of the journal), warfarin and the urgent
reversal of warfarin-induced coagulopathy were
reviewed and an overview of the newer direct oral
anticoagulant agents was provided. Part two,
contained herein, addresses the management of
antiplatelet agents in the surgical setting, followed
by general recommendations for the management
of anticoagulated patients in the perioperative
setting.
ANTIPLATELET AGENTS
The dramatic rise in the use of endovascular stents
in the treatment of cardiovascular and cerebrovas-
cular disease has greatly increased the use of dual
antiplatelet regimens to reduce acute and subacute
thrombosis risk.1 The two most commonly encoun-
tered agents are aspirin (ASA) and clopidogrel
(Plavix: Bristol-Meyers Squibb, New York,
New York, USA). ASA’s pharmacological effect on
platelets is through the irreversible acetylation and
inhibition of platelet cyclooxygenase-1, a critical
enzyme involved in the production of thromboxane
A2. The release of thromboxane A2 stimulates the
recruitment and activation of further platelets and
increases platelet aggregation.2 Clopidogrel is
within the thienopyridine class of drugs that blocks
the P2Y12 receptor on platelets for adenosine
diphosphate (ADP), thus irreversibly preventing
platelet activation.2 Since clopidogrel is a prodrug
that requires activation by hepatic P450 enzymes,
significant variability of antiplatelet activity may
exist between patients. There are no specific rever-
sal agents for clopidogrel. Since its effects are irre-
versible, the resultant platelet inhibition lasts for
the lifespan of the platelet, ∼7–9 days.
Antiplatelet therapy in acute coronary
syndrome and coronary stent placement
Current guidelines in cardiology recommend (class
IA) dual antiplatelet therapy with ASA and clopido-
grel for a minimum of 1 month and up to a year
for patients treated medically or with bare-metal
stents. For patients with drug-eluting stents, dual
therapy is recommended for a minimum of
1 year.3 4 Cessation of clopidogrel is associated
with increased risk of thrombosis in patients with
acute coronary syndrome and in patients with stent
placement, particularly in the first 90 days.3
Premature discontinuation of antiplatelet therapy is
the strongest predictor of stent thrombosis for both
bare-metal and drug-eluting stents.4–9 In one study,
premature discontinuation of antiplatelet therapy
resulted in a 29% thrombosis rate and a 45% mor-
tality for patients with stent thrombosis.4 The cal-
culated HR for all stent thrombosis (subacute and
late) was 89.78 for premature antiplatelet therapy
discontinuation.
Restoring platelet function
The use of antiplatelet agents has been shown to
increase bleeding risks after surgery and trauma
and to increase the risk of spontaneous and post-
traumatic intracranial bleeding.10 11 However,
assessing this risk is dependent on actual platelet
function. Platelet counts alone demonstrate limited
correlation with bleeding risk. The indications for
providing agents to restore platelet function in the
setting of bleeding risk are controversial.10–12 For
ASA-induced platelet dysfunction, intravenous
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desmopressin has been shown to restore activity, though little
clinical outcome data are available.10 13 The indications for the
use of platelet transfusion to reverse the antiplatelet activity of
clopidogrel and ASA have not been established and clinical data
are variable.10–12 The half-life of clopidogrel is 6 hours, and
thus therapeutic levels should be fairly low after 3–4 half-lives.
Transfusion of platelets has been shown to reduce the antiplate-
let effect, though the dosing and timing remain unclear.14 An
ongoing multicenter study is currently underway to investigate
the utility of platelet transfusion in cerebral hemorrhage, but no
results have been published.15 Currently, to determine if platelet
transfusion is indicated, an assessment of platelet function
should be undertaken.
Assessing platelet function
Assessing platelet function and its contribution to bleeding risk
in elective and emergent settings remains challenging, particu-
larly with the use of aspirin or clopidogrel. Platelet activity com-
prises 80% of overall clot strength and the remaining 20% is
determined by fibrin. As such, overall clot strength is probably
best assessed using a whole blood assay rather than serum-based
testing of platelet function alone. Moreover, little correlation
exists between platelet count and clot strength. Patients can have
normal platelet counts with markedly impaired platelet function
in conditions such as von Willebrand factor deficiency and
uremia. Individual tests are discussed in the sections below and
summarized in table 1.
Bleeding time: Although there are many tests to assess platelet
function, there is no test that is readily clinically available, pro-
spectively validated, and reliable to guide transfusion strategy or
assess risk of bleeding. The bleeding time is one of the oldest
tests which aimed to assess platelet function. This test involves
incising the skin and blotting the hemorrhage to determine time
to clot formation and arrest of bleeding. However, test results
are obfuscated by differences in the amount of pressure applied.
Furthermore, since the test involves making an incision, it
cannot be repeated serially.
Aggregometry: This test likely represents the most accurate
way to measure platelet function. However, this test is not
readily available and is not portable. Aggregometry can be per-
formed by measuring light transmittance or electrical imped-
ance. Light transmission aggregometry (LTA) is performed by
adding a known agonist, such as arachidonic acid (AA) or ADP,
to a platelet rich medium.16 Note that this test is not performed
using whole blood. Platelets that are stimulated by the agonist
will aggregate, thereby increasing light transmission in the
medium. Thus, platelet activity is directly proportional to light
transmittance. Impedance aggregometry is based on the same
principle as LTA but is performed on whole blood.17 This
modality uses an electrical current to stimulate the platelet
before and after addition of AA/ADP. Platelets that are stimu-
lated bind to the electrodes, thereby increasing impedance. The
degree of platelet inhibition due to aspirin or an ADP-receptor
antagonist, such as clopidogrel, is assessed as a function of
change in impedance before and after addition of the appropri-
ate agonist. Both LTA and impedance aggregometry are best
used by assessing baseline platelet function versus stimulated
platelet function to determine actual versus maximal platelet
activity. Unfortunately, there are no reference values (ie, normal
values) to gauge the probability of bleeding.
PFA-100 and VerifyNow: Two more commonly available and
more easily performed assays which also seek to measure plate-
let function are the PFA-100 (Siemens Medical, Malvern,
Pennsylvania, USA) and VerifyNow (Accriva Diagnostics, San
Diego, California, USA).18–20 PFA-100 is currently approved
only to detect the presence of aspirin. This test is performed by
exposing flowing whole blood to an aperture lined with epi-
nephrine. As the platelets activate, they seal the aperture. Thus,
‘closing time’ is inversely proportional to platelet activity.
VerifyNow is also a whole blood assay that is based on the prin-
ciples of LTA and can detect platelet inhibition due to either
aspirin or ADP-receptor blocking agents. This test is performed
by placing a specimen of whole blood in a cassette that includes
fibrin bonded beads. AA/ADP are added as agonists. As the
beads dissolve, the fibrin interacts with the platelets and stimu-
lates them. Light is transmitted across the cassette, and, akin to
LTA, increase in light transmittance is directly proportional to
platelet activity. Although both PFA-100 and VerifyNow have
reference ranges regarding the degree of inhibition recom-
mended to prevent thrombus formation, there are no validated
values regarding the degree of inhibition associated with clot
formation or cessation of hemorrhage.
Thrombelastography-platelet mapping (TEG-PM): This test
assesses platelet function using a whole blood assay.21 Blood is
placed in a cup, a pin inserted, and the cup rotates. Kaolin, a
clotting catalyst, is added to the specimen to start the clotting
process and a graph of clot strength versus time is generated
(figure 1). The maximum amplitude (MA-CK) represents the
total potential clot strength, inclusive of both the platelet and
fibrin component. The specimen is then re-analyzed with
heparin and reptilase added. This allows measurement of the
fibrin contribution to the clot (MA-F) which can then be sub-
tracted from the MA-CK to determine the platelet contribution
to clot strength. The specimen is then re-analyzed with ADP or
AA added to determine the change in clot strength related to
each agonist. This allows selective measurement of the degree of
inhibition of platelet function due to the AA and ADP receptors,
thereby quantifying the anticoagulant effect due to aspirin and
ADP receptor antagonist medications (figure 2). As with the
aforementioned tests, however, there are no reference ranges for
the degree of inhibition associated with thrombosis or coagulo-
pathy. Recent studies suggest that the degree of inhibition in
normal volunteers is <5%, whereas the degree of inhibition can
be as high as 30–60% in injured or critically ill patients.22–24
Thus, as with the other tests of platelet function, although
TEG-PM is able to detect platelet dysfunction, clinical
Table 1 Basic characteristics and interpretation of commonly used
assays to assess platelet function
Test Medium Interpretation Comments
Light
transmission
aggregometry
Plasma Increased light
transmission α increased
platelet function
Does not account for
effect of blood cells
on clotting
Impedance
aggregometry
Whole
blood
Increased impedance α
increased platelet
function
PFA-100 Whole
blood
Decreased closure time
α increased platelet
function
Not approved for
detection of
clopidogrel
VerifyNow Whole
blood
Akin to light
transmission
aggregometry
TEG platelet
map
Whole
blood
Directly reports the
percentage of inhibition
in maximal platelet
function
Variable and high
degree of inhibition
noted due to illness
and injury
TEG, thrombelastography-platelet mapping.
2 Yeung LYY, et al. Trauma Surg Acute Care Open 2016;1:1–7. doi:10.1136/tsaco-2016-000022
Open Access
 o
n
 30 M
ay 2018 by guest. Protected by copyright.
http://tsaco.bmj.com/
Traum
a Surg Acute Care O
pen: first published as 10.1136/tsaco-2016-000022 on 13 July 2016. Downloaded from
 
judgement is needed to apply the results appropriately in any
particular scenario. Until now, there are no tests akin to the
International Normalized Ratio (INR) in patients using warfarin
in that no test measuring platelet function can be readily inter-
preted to determine the propensity for bleeding or clotting in
all instances.
PERIOPERATIVE MANAGEMENT OF LONG-TERM
ANTICOAGULATION
The perioperative management of patients who require long-
term anticoagulation requires careful analysis of the risk-benefit
ratio, balancing the risk of thromboembolism versus the risk of
hemorrhage. Determining the periprocedural risk of thrombo-
embolism requires an understanding of the condition for which
the drug is being prescribed. The most common indications
include non-valvular atrial fibrillation, venous thromboembolic
disease, and the presence of mechanical heart valves.
Quantifying the risk associated with the specific indication for
an individual patient is required to appropriately manage antic-
oagulation in the periprocedural period.
Assessing thrombotic risk
Thrombotic risk for individual patients varies by each of the
common indications as well as by the presence or absence of
individual risk factors. The methods of assessing the risks for
each of the common indications are discussed below.
Non-valvular atrial fibrillation: The risk of stroke or arterial
thromboembolism in non-valvular AF can be gauged by using
one of a number of scoring systems, the most common
being the CHADS2 or expanded CHA2DS2-VASc scores.
25 26
For CHADS2 (see table 2), points are assigned for five risk
factors: congestive heart failure, hypertension, age >75 years,
diabetes, and a history of stroke, transient ischemic attack, or
thromboembolism.
In the expanded scoring system CHA2DS2-VASc (table 3),
additional points are given for the presence of vascular disease,
age between 65–74 years, and female gender.
For both systems, the annual risk of stroke increases with the
total number of points (see tables 4 and 5) A score greater than
two points is generally considered high risk for thromboembol-
ism and an indication for long-term anticoagulation.25 26
Venous thromboembolism: For a history of venous thrombo-
embolism (VTE), patients are grouped into low-risk, intermediate-
risk, and high-risk categories as outlined below.27
▸ Low risk (<5% annual risk of VTE): a history of VTE
>12 months ago;
▸ Intermediate risk (a 5–10% annual risk of VTE): a history of
VTE within 3–12 months, a ‘non-severe’ thrombophilia such
as Factor V Leiden or a prothrombin gene mutation, or an
active cancer (treated within 6 months or currently undergo-
ing palliative treatment)
▸ High risk (>10% annual risk of VTE): VTE within
3 months, or a ‘severe’ thrombophilia such as Protein C/S/
antithrombin deficiency or presence of antiphospholipid
antibodies.
Prosthetic heart valves: Patients with heart valve replacement
are at increased risk of embolic event. Bioprosthetic valves are at
much lower risk than mechanical valves and oral anticoagulant
therapy is typically required only for the first 3 months after
placement followed by antiplatelet therapy.28 All mechanical
prosthetic heart valves require long-term anticoagulation but the
risk of emboli and therapeutic targets vary depending on the
valve type and position (aortic vs mitral).28 The risk of embolic
event may be grouped into either intermediate or high-risk
groups as determined by position, valve type, and the presence
or absence of additional thrombotic risk factors.
▸ Intermediate risk: (1) patients with aortic bileaflet or
current-generation single tilting disc valves with no risk
factors for thromboembolism, (2) patients with bioprosthetic
Figure 1 Standard TEG tracing.
R time is reflective of enzyme/
coagulation factor deficiency. α Angle
is reflective of the thrombin burst.
Maximal amplitude (MA) consists of
80% of platelet activity and 20% of
fibrinogen. TEG, thrombelastography-
platelet mapping.
Figure 2 TEG platelet map tracing.
Note the insert which shows the
degree of platelet inhibition both as a
percentage of total as well as the
actual MA associated with the
pathway. This assay shows 75.5%
inhibition in the ADP pathway. ADP,
adenosine diphosphate; MA, maximal
amplitude; TEG, thrombelastography-
platelet mapping.
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valves and atrial fibrillation, atrial thrombus or enlargement,
prior stroke or TIA >6 months, or with hypertension, dia-
betes, congestive heart failure, or age >75 years.
▸ High risk: (1) patient with aortic caged-ball type and older
generation valves, (2) any mechanical valve with atrial fibril-
lation, atrial thrombus or enlargement, prior stroke or TIA,
congestive heart failure, and hypercoagulable conditions, (3)
all mechanical valves in the mitral position.
For patients with intermediate risk, the recommended target
of vitamin K antagonism anticoagulation therapy is an INR of
2.5 and for those in the high-risk group an INR of 3.0 is
recommended.28
Assessing hemorrhagic risk
Remaining on anticoagulation in the periprocedural period must
be balanced against the risk of periprocedural hemorrhage.
While this can be difficult to quantify, the factors generally
taken into account are patient characteristics and the nature of
the procedure they are to undergo. Numerous scoring tools
have been proposed to quantify patient hemorrhage risk includ-
ing the Outpatient Bleeding Risk Index, the HEMORR2HAGES
score, and the HAS-BLED score.29 30 The HAS-BLED score is
the most commonly employed tool that has been validated to
predict bleeding risk during bridging of anticoagulation.31 The
HAS-BLED score assigns a point value to each of the following
risk factors: hypertension, abnormal renal or liver function,
stroke, bleeding history, labile INR, elderly age, and drugs
(aspirin, non-steroidal anti-inflammatory drugs, alcohol) and
groups patients into low, medium, and high risk of bleeding (see
tables 6 and 7).
These systems can be used to gauge the risk of bleeding when
considering recommendations for periprocedural management.
The nature of the procedure should also be considered when
assessing bleeding risk. While there is no firm scoring system to
quantify this, procedures can generally be grouped into high-
risk (2–4%) and low-risk (0–2%) procedures.
▸ High risk: cardiovascular, orthopedic, head and neck cancer
or urological in nature, or those >45 min in length.
▸ Low risk: procedures anticipated to be <45 min, cutaneous,
or relatively straightforward such as a cholecystectomy.
Also to be taken into account are those situations where a
small amount of bleeding can have serious consequences, such
as ophthalmological procedures, or those where bleeding may
not be easily detected.
After the risks of both thromboembolism and hemorrhage
have been weighed against each other, the current anticoagula-
tion status of the patient must be evaluated. It is possible to
measure direct levels of dabigatran and rivaroxaban, with dif-
ferent recommendations for procedural timing according to
plasma concentration. Patients found to have levels <30 ng/
mL are generally considered safe for surgery. Those with 30–
200 ng/mL are advised to delay procedures at least 12 hours
if possible, followed by a recheck of plasma levels. Patients
with levels between 200 and 400ng/mL should delay inter-
ventions at least 24 hours, and those with levels >400 ng/mL
are considered at major risk of uncontrollable hemorrhage
and should consider hemodialysis or other removal methods.
However, in order to measure plasma concentrations, this
requires access to mass spectrometry, which is not always
readily available.
In the absence of direct level measurements, estimates can be
obtained with other qualitative estimates or indirect quantitative
measurements. Warfarin can be quantitatively estimated with
INR measurement. Direct thrombin inhibitors such as dabiga-
tran can be qualitatively estimated using activated partial
thromboplastin time, prothrombin (PT), or thrombin time or
quantitatively measured with dilute thrombin time, ecarin
chromogenic assay, or ecarin clotting time. Factor Xa inhibitors
such as rivaroxaban or apixaban can be estimated via PT or
Table 2 CHAD2 scoring system for assessing thromboembolic risk
Condition Points
C Congestive heart failure 1
H Hypertension: blood pressure consistently above 140/90 mm Hg
(or treated hypertension on medication)
1
A Age ≥75 years 1
D Diabetes mellitus 1
S2 Prior Stroke or TIA or Thromboembolism 2
TIA, transient ischemic attack.
Table 3 CHA2DS2-VASc scoring system for assessing
thromboembolic risk
Condition Points
C Congestive heart failure (or Left ventricular systolic dysfunction) 1
H Hypertension: blood pressure consistently above 140/90 mm Hg
(or treated hypertension on medication)
1
A2 Age ≥75 years 2
D Diabetes Mellitus 1
S2 Prior Stroke or TIA or thromboembolism 2
V Vascular disease (eg, peripheral artery disease, myocardial
infarction, aortic plaque)
1
A Age 65–74 years 1
Sc Sex category (ie, female sex) 1
TIA, transient ischemic attack.
Table 4 Stroke risk by CHADS2 score
CHADS2 score Stroke risk % 95% CI
0 1.9 1.2 to 3.0
1 2.8 2.0 to 3.8
2 4.0 3.1 to 5.1
3 5.9 4.6 to 7.3
4 8.5 6.3 to 11.1
5 12.5 8.2 to 17.5
6 18.2 10.5 to 27.4
Table 5 Stroke risk by CHA2DS2-VASc score
CHA2DS2-VASc score Stroke Risk % 95% CI
0 0 –
1 1.3 –
2 2.2 –
3 3.2 –
4 4.0 –
5 6.7 –
6 9.8 –
7 9.6 –
8 12.5 –
9 15.2 –
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measured with chromogenic antifactor Xa. Antiplatelet agents
are gauged qualitatively with optical aggregometry or quanti-
tated with flow cytometry, platelet function assay, or thromboe-
lastography. While these tests can give an estimate of the
patient’s current status, they are far from exact and can only
serve as an indicator of anticipated complications in the event of
an emergency, although they may be useful in attempting to
reduce risks in semiurgent or elective cases.
Management of anticoagulation in elective cases
Three factors that need to be considered in the case of elective
surgeries are (1) when to stop, (2) whether to bridge, and (3)
when to restart.
Discontinuation prior to surgery: General recommendations
are summarized in the table (table 8) below and are according
to the American College of Chest Physician 2012 Guidelines
published in Chest, the RE-LY trial published in Circulation
2012, the ROCKETAF trial, and the manufacturer’s recommen-
dations.32–35
Patients whose procedures are at low risk of bleeding may
continue oral anticoagulation therapy. This is particularly true
for high-risk patients such as those with mechanical heart
values.
Indications for bridging: The need for perioperative bridging
is decided on by taking into account the patient’s thrombo-
embolism and hemorrhage risk and stratifying them into low,
medium and high risk. In the case of warfarin, recommenda-
tions are summarized in the flow chart below (figure 3),
adapted from the 2012 American College of Chest Physicians
Guidelines.32 Bridging may be achieved either with intravenous
unfractionated heparin or with subcutaneous low-molecular-
weight heparin. Temporary interruption of vitamin K antagon-
ism agents, without bridging while the INR is subtherapeutic, is
recommended for patients with bileaflet mechanical aortic valve
replacements and no other risk factors.28 All other mechanical
valve settings should undergo bridging.
Efficacy of bridging: Whether or not outcomes are really
better with bridging patients on vitamin K antagonists remains
uncertain. A meta-analysis published by Siegal et al35 in 2012
found that the rate of thromboembolism was equivalent in
patients who underwent periprocedural heparin bridging;
however, there was a significantly higher number of patients
who had major bleeding complications in those undergoing
heparin bridging. These results were replicated in a randomized
controlled trial by Douketis et al36 in 2015 demonstrating non-
inferiority between patients undergoing no bridging versus
those with low-molecular-weight heparin bridging and a signifi-
cant reduction of major bleeding complications in those patients
who did not undergo bridging.
With the non-vitamin K antagonist oral anticoagulants, no
strong evidence to support bridging exists currently. These
Table 6 HAS-BLED score to assess bleeding risk
HAS-BLED risk Score
Hypertension 1
Abnormal
Renal function 1
Liver function 1
Stroke 1
Bleeding 1
Labile INRs 1
Elderly: age >65 years 1
Drugs 1
Alcohol 1
Hypertension: systolic blood pressure >160 mm Hg; Abnormal renal function:
presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L;
abnormal hepatic function: chronic hepatic disease or biochemical evidence of
significant hepatic derangement (eg, bilirubin >2× upper limit of normal, in
association with aspartate aminotransferase/alanine aminotransferase/alkaline
phosphatase >3× upper limit of normal, etc); ‘Bleeding’ refers to previous bleeding
history and/or predisposition to bleeding (eg, bleeding diathesis, anemia); ‘Labile
INRs’ refer to unstable/high INRs or poor time in therapeutic range (eg, <60%);
Drugs/alcohol use refers to concomitant use of drugs, such as antiplatelet agents,
nonsteroidal anti-inflammatory drugs, alcohol abuse, etc.
INR, International Normalized Ratio.
Table 7 Risk of bleeding by HAS-BLED score
Score
Bleeding risk classification
(% bleeds/100 patient-years)
0–1 Low risk (1.1%)
2 Intermediate risk (1.9%)
>3 High risk (4.9%)
Table 8 Recommendations for timing of discontinuation of
anticoagulation for elective surgery
Drug Timing of discontinuation
Warfarin 5 days
Direct thrombin inhibitors
(dabigatran)
CrCl ≥50 mL/min: 1–2 days
CrCl <50 mL/min: 3–5 days
CrCl (mL/
min)
Bleed risk:
low
Bleed risk: high
(days)
≥50 24 hours 2-3
30–50 2 days 2-3
<30 2–4 days >5
Factor Xa inhibitors
Rivaroxaban (Xarelto) ≥24 hours
ROCKET AF: ≥3 days
Apixaban (Eliquis) Low-bleed risk: ≥24 hours
High-bleed risk: ≥48 hours
Antiplatelet agents
Aspirin High-CV risk/minor: continue
Low CV/high-bleed risk: 7–10 days
Clopidogrel 5 days
Stents: bare metal stents—delay surgery for 6 weeks; drug eluding stents delay
surgery for 6–12 months due to risk of occlusion; otherwise, consider continuing
agents.
CV, cardiovascular.
Figure 3 Algorithm for perioperative bridging of warfarin. INR,
International Normalized Ratio; LMWH, low-molecular-weight heparin;
UFH, unfractionated heparin.
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anticoagulants have a shorter half-life and faster onset making
the benefits of bridging less obvious. A study from the European
Dresden registry from 2014 demonstrated that in patients taking
nonvitamin K antagonists, heparin bridging did not reduce car-
diovascular events, and major bleeding again was more frequent
with bridging than without.37 Additionally, the HASBLED
scoring system used to gauge the risk of hemorrhage can also be
used to estimate risk of hemorrhage heparin bridging during
warfarin cessation.31 Recommendations are unclear regarding
the efficacy and need for bridging with DOACs.
Re-initiation of oral anticoagulation: The decision to restart
anticoagulation after a procedure is again determined by weigh-
ing the risks for thromboembolism against that of hemorrhage.
If hemostasis is assured after the procedure, vitamin K antago-
nists can be restarted 6–24 hours after surgery as therapeutic
levels will take several days to reach. If periprocedural bridging
is being used, patients at low risk of bleeding can resume bridg-
ing at 24 hours and those at higher bleed risk at 48–72 hours
for all high-risk patients. Non-vitamin K antagonists could
potentially be resumed after 6–24 hours in patients with low
bleeding risk if hemostasis is assured, bearing in mind that these
agents have a much faster time of onset. Those with higher
bleeding risk should wait 48–72 hours prior to restarting and
could be considered for bridging with heparin if the risk of
thromboembolism is also high.
Management of anticoagulation in urgent/emergency cases
In cases where future planning and weighing risks and benefits
for periprocedural management cannot be accomplished, the
two main goals are initial management of anticoagulation fol-
lowed by employment of reversal strategies. Initial actions
include discontinuing the anticoagulant, delaying semiurgent
procedures as appropriate, and consideration of activated char-
coal for ingestions <2 hours prior.
Several reversal strategies in the urgent/emergent setting for
anticoagulant and antiplatelet therapies agents are summarized
below and reviewed in previous publications.38
Antiplatelet agents: Current recommendations suggest that
patients with active bleeding or at high risk of bleeding and
those who have platelet counts <50 000/mL undergo platelet
transfusion.38 Antiplatelet therapy has been shown to worsen
the outcome of patients with intracranial hemorrhage or trau-
matic brain injury.10 11 However, the indications for platelet
transfusion to restore platelet function remain controversial.10–12
Some authors and guidelines recommend transfusion of 5–
10 units of platelet concentrates in patients with intracranial
hemorrhage receiving antiplatelet therapy.38–40 However, the
efficacy of platelet transfusion in the setting of non-reversible
antiplatelet agents is not fully established, although research is
currently ongoing.15 There may also be some role for desmo-
pressin in the setting of ASA therapy, although indications have
not been well elucidated.10 13
Vitamin K antagonists: The first-line Food and Drug
Administration (FDA)-approved strategy is the intravenous infu-
sion of vitamin K, 1–10 mg intravenous over 30 min, followed
by prothrombin complex concentrates (KCentra) 25–50 units/kg
as second-line therapy. A third-line strategy is fresh frozen
plasma for an INR >2. Recombinant factor VII remains as an
option, although this is currently not approved by the FDA.
Direct thrombin inhibitors: dabigatran is the most commonly
prescribed direct thrombin inhibitor. Idarucizumab, a specific
antibody reversing agent, is now approved for use as the first-
line reversing agent for Dabigatran. First-line recommenda-
tions consist of Factor VIII Inhibitor Bypassing Activity (FEIBA)
50–100 units/kg, followed by PCCs 25–50 units/kg as a second-
line option. Recombinant Factor VII can be used as a 100 mg/kg
bolus, repeated as needed. Hemodialysis can also be effective in
clearing direct thrombin inhibitors from the bloodstream.
Factor Xa inhibitors: First-line reversal agents are 4 factor
PCCs 25–50 units/kg followed by FEIBA 50–100 units/kg (with
a maximum dose of 200 units/kg daily) as a second-line agent.
Target-specific agents such as andexanet α and PER977 are also
in the process of undergoing development and testing.
MANAGEMENT OF ANTIPLATELET THERAPY IN THE
PERIOPERATIVE PERIOD
Inadequate data are available to establish firm recommenda-
tions regarding cessation or continuation of antiplatelet therapy
in the elective or urgent perioperative setting. The risks of
bleeding and outcomes from bleeding must be weighed against
the thrombotic risks and substantial associated mortality.3–9
Studies of bleeding risk have provided conflicting information.
One randomized study involving only 52 patients receiving ASA
did not find a significant difference in the incidence of peri-
operative hemorrhage in patients undergoing cholecystectomy,
colorectal surgery, or inguinal hernia repair.41 Patients in this
study were randomized to stop aspirin for 5 days before and
after operation versus continuing aspirin throughout the peri-
operative period. A number of retrospective and prospective
cohort studies have examined the risk of bleeding with dual
antiplatelet therapy with disparate results.42 A recent systematic
review found no difference in the incidence of bleeding in
gastrointestinal surgery when all studies were considered.42 Of
the various studies performed, only one involved pancreatec-
tomy, five involved cholecystectomy, and eight involved endo-
scopic polypectomy. The largest study involving general surgery
patients included 1075 patients and similarly did not find a sig-
nificant difference in the probability of bleeding related to
ongoing use of single antiplatelet agents following various lap-
aroscopic operations.43 However, use of dual antiplatelet agents
was associated with a higher rate of hemorrhage in multivariable
analysis. In total, there is insufficient evidence on which to base
a recommendation regarding perioperative management of anti-
platelet therapy. Clinical discretion is needed to weigh the risk
of bleeding versus the risk of thrombosis.
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